Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Keryx Biopharmaceuticals Inc (NASDAQ:KERX)

4.56
Delayed Data
As of Dec 11
 -0.18 / -3.80%
Today’s Change
4.33
Today|||52-Week Range
8.38
-22.18%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 4
2016
Quarter 1
2017
Quarter 2
2017
Quarter 3
2017
Revenue and IncomeNet Revenues9.5M11.8M15.1M15.0M
 
 
 
 
 
Cost of Goods Sold26.0M5.1M5.0M6.7M
 
 
 
 
 
Depreciation And Amortization229.0K229.0K230.0K230.0K
 
 
 
 
 
 
Operating ExpensesGross Income-16.7M6.5M9.9M8.1M
 
 
 
 
 
General Expenses29.0M29.6M33.8M31.8M
 
 
 
 
 
Other Operating Expenses-11.8M0.000.000.00
 
 
Research And Development6.2M6.8M9.0M9.3M
 
 
 
 
 
Total Operating Expenses43.4M34.9M39.0M38.7M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-33.9M-23.1M-23.9M-23.7M
 
 
 
 
 
Extraordinary Credit0.000.00225.0K0.00
 
 
Interest Expense On Debt--0.0063.0M0.00
 
 
Other Expenses1.0K-3.0K-5.0K1.0K
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-33.8M-23.0M-86.5M-23.5M
 
 
 
 
 
Income Taxes-20.0K-20.0K-20.0K-20.0K
 
 
 
 
 
Net Income-33.8M-23.0M-86.5M-23.5M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS106.0M107.1M112.6M119.0M
 
 
 
 
 
Shares To Calculate EPS Diluted106.0M107.1M112.6M119.0M
 
 
 
 
 
 
Earnings Per ShareEPS-$0.32-$0.21-$0.77-$0.20
 
 
 
 
 
EPS Diluted-$0.32-$0.21-$0.77-$0.20